Mergers

KKR already holds a 17% stake in Biotage through its life sciences platform, Gamma Biosciences, and would gain full control if the deal proceeds.

The new facility is designed to accelerate the development of next-generation ADCs, targeted therapies that combine antibodies with potent cytotoxic agents to precisely attack tumor cells while minimizing harm to healthy tissues.

Under the terms of the agreement, Lexicon will complete specific preclinical activities before handing over the reins to Novo Nordisk for further development, manufacturing, and commercialization.

Elevated levels of lipoprotein (a) are linked to a heightened risk of atherosclerotic cardiovascular disease, affecting approximately one in five adults worldwide, potentially leading to severe health problems, including heart attacks and strokes.

This substantial investment will primarily support the clinical advancement of AGT-100216, which inhibits the histone deacetylase 6 (HDAC6) enzyme implicated in neurodegeneration and aging-related processes at the cellular level.